Glenmark Shares Rise on $700M AbbVie Licensing Deal, With $1.2B Milestones Ahead

Mumbai, September 10, 2025: Glenmark Pharmaceuticals shares rose 3.1% on Tuesday to settle at ₹2,116.25, closing after announcing a $700 million (₹6,000 crore) advance payment from US pharma major AbbVie. This amount is part of an exclusive deal, a worldwide licensing agreement for Ichnos Glenmark Innovation’s key investigational drug ISB 2001.

Details of the Licensing Agreement

AbbVie will now have exclusive development and marketing rights for ISB 2001 across North America, Europe, Japan, and Greater China as per the deal. Besides the $700 million advance payment, Glenmark may collect up to $1.2 billion (around ₹10,000 crore) in milestones and tiered royalties. Glenmark plans to keep rights in India as well as other emerging markets to capitalize on this drug.

ISB 2001: A Potential Breakthrough

Developed on the basis of IGI’s proprietary BEAT protein platform, ISB 2001 is in the Phase 1 development of clinical trials aiming at relapsed or refractory multiple myeloma cases. The US Food and Drug Administration (FDA) has granted ISB 2001 the official tags of ‘orphan drug’ and ‘fast-track’ for this drug. This drug has delivered encouraging results for BCMA CAR-T-treated patients. As of now, ISB 2001 is the sole trispecific antibody of its class being developed globally. Glenmark clarified that trispecifics will complement a wider treatment portfolio rather than function in isolation.

Stock Market Performance

Investor confidence was high after the announcement, with Glenmark’s stock closing at ₹2,116.25 on September 9, 2025, its highest level in a month. This bounce comes after sliding to a two-week low of ₹1,904 recently. Back in July, this stock already reached a 52-week high of ₹2,284.80, soon after Glenmark announced the deal.

Strategic Outlook

By 2030, Glenmark plans to make ISB 2001 a key contender in the $50 billion multiple myeloma market forecast. If clinical trials proceed as per the planned schedule, commercial launch is expected within four to five years. The $700 million advance amount will help expand the IGI’s pipeline, with some capital possibly disbursed to shareholders in the form of dividends.

Disclaimer:At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.